Vixarelimab granted Breakthrough Therapy designation in the US for the treatment of pruritus associated with Prurigo Nodularis

Vixarelimab is a human monoclonal antibody that targets oncostatin M receptor beta. The designation is based on data from a Phase 2a trial in which it was associated with a statistically significant reduction in weekly-average Worst-Itch Numeric Rating Scale at Week 8 vs. placebo

Source:

Biospace Inc.